Organs at risk in lung SBRT

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Lung stereotactic body radiotherapy (SBRT) is an accurate and precise technique to treat lung tumors with high ‘ablative’ doses. Given the encouraging data in terms of local control and toxicity profile, SBRT has currently become a treatment option for both early stage lung cancer and lung oligometastatic disease in patients who are medically inoperable or refuse surgical resection. Dose-adapted fractionation schedules and ongoing prospective trials should provide further evidence of SBRT safety trying to reduce toxicities and complications. In this heterogeneous scenario, a non-systematic review of dose constraints for lung SBRT was performed, including the main organs at risk in the thorax.

Original languageEnglish
Pages (from-to)131-138
Number of pages8
JournalPhysica Medica
Volume44
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Organs at Risk
Radiosurgery
organs
lungs
radiation therapy
Lung
Lung Neoplasms
toxicity
dosage
Dose Fractionation
thorax
Lung Diseases
Appointments and Schedules
schedules
Thorax
fractionation
safety
Safety
tumors
cancer

Keywords

  • Dose constraints
  • Lung SBRT
  • Organs at risk

ASJC Scopus subject areas

  • Biophysics
  • Radiology Nuclear Medicine and imaging
  • Physics and Astronomy(all)

Cite this

@article{e08071617f364e5bb03e53be6a141bdc,
title = "Organs at risk in lung SBRT",
abstract = "Lung stereotactic body radiotherapy (SBRT) is an accurate and precise technique to treat lung tumors with high ‘ablative’ doses. Given the encouraging data in terms of local control and toxicity profile, SBRT has currently become a treatment option for both early stage lung cancer and lung oligometastatic disease in patients who are medically inoperable or refuse surgical resection. Dose-adapted fractionation schedules and ongoing prospective trials should provide further evidence of SBRT safety trying to reduce toxicities and complications. In this heterogeneous scenario, a non-systematic review of dose constraints for lung SBRT was performed, including the main organs at risk in the thorax.",
keywords = "Dose constraints, Lung SBRT, Organs at risk",
author = "{De Rose}, F. and D. Franceschini and G. Reggiori and A. Stravato and P. Navarria and Ascolese, {A. M.} and S. Tomatis and P. Mancosu and M. Scorsetti",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.ejmp.2017.04.010",
language = "English",
volume = "44",
pages = "131--138",
journal = "Physica Medica",
issn = "1120-1797",
publisher = "Associazione Italiana di Fisica Medica",

}

TY - JOUR

T1 - Organs at risk in lung SBRT

AU - De Rose, F.

AU - Franceschini, D.

AU - Reggiori, G.

AU - Stravato, A.

AU - Navarria, P.

AU - Ascolese, A. M.

AU - Tomatis, S.

AU - Mancosu, P.

AU - Scorsetti, M.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Lung stereotactic body radiotherapy (SBRT) is an accurate and precise technique to treat lung tumors with high ‘ablative’ doses. Given the encouraging data in terms of local control and toxicity profile, SBRT has currently become a treatment option for both early stage lung cancer and lung oligometastatic disease in patients who are medically inoperable or refuse surgical resection. Dose-adapted fractionation schedules and ongoing prospective trials should provide further evidence of SBRT safety trying to reduce toxicities and complications. In this heterogeneous scenario, a non-systematic review of dose constraints for lung SBRT was performed, including the main organs at risk in the thorax.

AB - Lung stereotactic body radiotherapy (SBRT) is an accurate and precise technique to treat lung tumors with high ‘ablative’ doses. Given the encouraging data in terms of local control and toxicity profile, SBRT has currently become a treatment option for both early stage lung cancer and lung oligometastatic disease in patients who are medically inoperable or refuse surgical resection. Dose-adapted fractionation schedules and ongoing prospective trials should provide further evidence of SBRT safety trying to reduce toxicities and complications. In this heterogeneous scenario, a non-systematic review of dose constraints for lung SBRT was performed, including the main organs at risk in the thorax.

KW - Dose constraints

KW - Lung SBRT

KW - Organs at risk

UR - http://www.scopus.com/inward/record.url?scp=85017515961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017515961&partnerID=8YFLogxK

U2 - 10.1016/j.ejmp.2017.04.010

DO - 10.1016/j.ejmp.2017.04.010

M3 - Review article

C2 - 28433508

AN - SCOPUS:85017515961

VL - 44

SP - 131

EP - 138

JO - Physica Medica

JF - Physica Medica

SN - 1120-1797

ER -